RATIONALE: Ex vivo, bronchial epithelial cells from people with asthma are more susceptible to rhinovirus infection caused by deficient induction of the antiviral protein, IFN-β. Exogenous IFN-β restores antiviral activity. OBJECTIVES: To compare the efficacy and safety of inhaled IFN-β with placebo administered to people with asthma after onset of cold symptoms to prevent or attenuate asthma symptoms caused by respiratory viruses. METHODS: A total of 147 people with asthma on inhaled corticosteroids (British Thoracic Society Steps 2-5), with a history of virus-associated exacerbations, were randomized to 14-day treatment with inhaled IFN-β (n = 72) or placebo (n = 75) within 24 hours of developing cold symptoms and were assessed clinically, with relevant samples collected to assess virus infection and antiviral responses. MEASUREMENTS AND MAIN RESULTS: A total of 91% of randomized patients developed a defined cold. In this modified intention-to-treat population, asthma symptoms did not get clinically significantly worse (mean change in six-item Asthma Control Questionnaire <0.5) and IFN-β treatment had no significant effect on this primary endpoint, although it enhanced morning peak expiratory flow recovery (P = 0.033), reduced the need for additional treatment, and boosted innate immunity as assessed by blood and sputum biomarkers. In an exploratory analysis of the subset of more difficult-to-treat, Step 4-5 people with asthma (n = 27 IFN-β; n = 31 placebo), Asthma Control Questionnaire-6 increased significantly on placebo; this was prevented by IFN-β (P = 0.004). CONCLUSIONS: Although the trial did not meet its primary endpoint, it suggests that inhaled IFN-β is a potential treatment for virus-induced deteriorations of asthma in difficult-to-treat people with asthma and supports the need for further, adequately powered, trials in this population. Clinical trial registered with www.clinicaltrials.gov (NCT 01126177).
RATIONALE: Ex vivo, bronchial epithelial cells from people with asthma are more susceptible to rhinovirus infection caused by deficient induction of the antiviral protein, IFN-β. Exogenous IFN-β restores antiviral activity. OBJECTIVES: To compare the efficacy and safety of inhaled IFN-β with placebo administered to people with asthma after onset of cold symptoms to prevent or attenuate asthma symptoms caused by respiratory viruses. METHODS: A total of 147 people with asthma on inhaled corticosteroids (British Thoracic Society Steps 2-5), with a history of virus-associated exacerbations, were randomized to 14-day treatment with inhaled IFN-β (n = 72) or placebo (n = 75) within 24 hours of developing cold symptoms and were assessed clinically, with relevant samples collected to assess virus infection and antiviral responses. MEASUREMENTS AND MAIN RESULTS: A total of 91% of randomized patients developed a defined cold. In this modified intention-to-treat population, asthma symptoms did not get clinically significantly worse (mean change in six-item Asthma Control Questionnaire <0.5) and IFN-β treatment had no significant effect on this primary endpoint, although it enhanced morning peak expiratory flow recovery (P = 0.033), reduced the need for additional treatment, and boosted innate immunity as assessed by blood and sputum biomarkers. In an exploratory analysis of the subset of more difficult-to-treat, Step 4-5 people with asthma (n = 27 IFN-β; n = 31 placebo), Asthma Control Questionnaire-6 increased significantly on placebo; this was prevented by IFN-β (P = 0.004). CONCLUSIONS: Although the trial did not meet its primary endpoint, it suggests that inhaled IFN-β is a potential treatment for virus-induced deteriorations of asthma in difficult-to-treat people with asthma and supports the need for further, adequately powered, trials in this population. Clinical trial registered with www.clinicaltrials.gov (NCT 01126177).
Authors: Ronald L Sorkness; Guillermo Gonzalez-Fernandez; Erin E Billmeyer; Michael D Evans; James E Gern; Nizar N Jarjour Journal: J Allergy Clin Immunol Date: 2008-09-05 Impact factor: 10.793
Authors: H Panitch; D S Goodin; G Francis; P Chang; P K Coyle; P O'Connor; E Monaghan; D Li; B Weinshenker Journal: Neurology Date: 2002-11-26 Impact factor: 9.910
Authors: L Kappos; A Traboulsee; C Constantinescu; J-P Erälinna; F Forrestal; P Jongen; J Pollard; M Sandberg-Wollheim; C Sindic; B Stubinski; B Uitdehaag; D Li Journal: Neurology Date: 2006-09-26 Impact factor: 9.910
Authors: Annemarie Sykes; Jonathan Macintyre; Michael R Edwards; Ajerico Del Rosario; Jennifer Haas; Vera Gielen; Onn Min Kon; Mark McHale; Sebastian L Johnston Journal: Thorax Date: 2013-10-14 Impact factor: 9.139
Authors: Peter A B Wark; Sebastian L Johnston; Fabio Bucchieri; Robert Powell; Sarah Puddicombe; Vasile Laza-Stanca; Stephen T Holgate; Donna E Davies Journal: J Exp Med Date: 2005-03-21 Impact factor: 14.307
Authors: M R Edwards; N Regamey; M Vareille; E Kieninger; A Gupta; A Shoemark; S Saglani; A Sykes; J Macintyre; J Davies; C Bossley; A Bush; S L Johnston Journal: Mucosal Immunol Date: 2012-12-05 Impact factor: 7.313
Authors: Y-P Liu; V Rajamanikham; M Baron; S Patel; S K Mathur; E A Schwantes; C Ober; D J Jackson; J E Gern; R F Lemanske; J A Smith Journal: Clin Exp Allergy Date: 2017-03 Impact factor: 5.018
Authors: Elizabeth A Schwantes; Loren C Denlinger; Michael D Evans; James E Gern; Nizar N Jarjour; Sameer K Mathur Journal: J Allergy Clin Immunol Date: 2015-03-14 Impact factor: 10.793
Authors: Michelle A Gill; Andrew H Liu; Agustin Calatroni; Rebecca Z Krouse; Baomei Shao; Allison Schiltz; James E Gern; Alkis Togias; William W Busse Journal: J Allergy Clin Immunol Date: 2017-09-01 Impact factor: 10.793
Authors: Richard Hewitt; Hugo Farne; Andrew Ritchie; Emma Luke; Sebastian L Johnston; Patrick Mallia Journal: Ther Adv Respir Dis Date: 2015-11-26 Impact factor: 4.031